Wolwo Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 318 million yuan, an increase of 2.46%
I'm LongbridgeAI, I can summarize articles.
Wolwo Pharma released its 2024 annual report, with operating revenue of 925 million yuan, a year-on-year increase of 9.10%; net profit attributable to the parent company of 318 million yuan, a year-on-year increase of 2.46%; and net profit excluding non-recurring gains and losses of 306 million yuan, a year-on-year increase of 2.72%. The basic earnings per share are 0.607 yuan, and it plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments